AAPL 171.29 -4.1305% MSFT 429.37 0.9736% GOOG 148.74 -0.628% GOOGL 147.6 -0.7664% AMZN 178.15 0.0% NVDA 914.35 1.1762% META 507.76 0.4431% TSLA 172.82 -1.6168% TSM 139.45 1.9744% LLY 770.26 -0.3364% V 290.37 0.3768% AVGO 1348.0 5.6426% JPM 199.06 1.3905% UNH 491.69 -0.5139% NVO 129.83 -0.4066% WMT 61.45 0.3265% LVMUY 182.95 -1.8193% XOM 113.49 0.4425% LVMHF 913.224 -2.0146% MA 488.64 0.1229%
Last update at 2024-01-23T20:01:58.471697Z
Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
Income before tax | 34.77M | -9.72100M | -68.87600M | -55.35000M | -65.33600M |
Minority interest | - | - | - | - | - |
Net income | 35.38M | -25.68700M | -69.78700M | -53.53600M | -65.33600M |
Selling general administrative | 23.86M | 20.94M | 18.91M | 16.39M | 18.24M |
Selling and marketing expenses | - | - | - | - | - |
Gross profit | 110.78M | 85.08M | 16.60M | 6.68M | 0.90M |
Reconciled depreciation | 1.29M | 1.25M | 0.73M | 2.03M | 0.97M |
Ebit | 14.54M | -4.59700M | -56.82100M | -52.45500M | -65.98700M |
Ebitda | 16.16M | -4.58200M | -56.73200M | -53.76100M | -65.01200M |
Depreciation and amortization | 1.62M | 0.01M | 0.09M | -1.30600M | 0.97M |
Non operating income net other | 23.26M | -2.28000M | -10.49900M | - | - |
Operating income | 14.54M | -4.59700M | -56.82100M | -52.45500M | -65.02200M |
Other operating expenses | 96.24M | 89.67M | 73.42M | 59.13M | 65.92M |
Interest expense | 3.03M | 2.84M | 1.56M | 1.52M | 1.49M |
Tax provision | -0.60900M | 15.97M | - | - | - |
Interest income | 0.98M | 2.80M | 1.24M | 0.83M | 1.05M |
Net interest income | -3.03100M | -2.84400M | -1.55600M | -1.51900M | -1.49400M |
Extraordinary items | - | - | - | - | - |
Non recurring | - | - | - | - | - |
Other items | - | - | - | - | - |
Income tax expense | -0.60900M | 15.97M | 0.91M | -1.81400M | 1.18M |
Total revenue | 110.78M | 85.08M | 16.60M | 6.68M | 0.90M |
Total operating expenses | 96.24M | 89.67M | 73.42M | 59.13M | 65.92M |
Cost of revenue | - | - | - | 42.74M | 47.69M |
Total other income expense net | 20.23M | -5.12400M | -12.05500M | -2.89500M | 1.18M |
Discontinued operations | - | - | - | - | - |
Net income from continuing ops | 35.38M | -25.68700M | -68.87600M | -55.35000M | -65.33600M |
Net income applicable to common shares | 35.38M | -25.68700M | -68.87600M | -55.35000M | -65.33600M |
Preferred stock and other adjustments | - | - | - | - | - |
Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
Total assets | 165.89M | 159.88M | 165.44M | 99.57M | 44.48M |
Intangible assets | - | - | - | - | - |
Earning assets | - | - | - | - | - |
Other current assets | 3.78M | 6.47M | 5.43M | 1.77M | 4.67M |
Total liab | 72.06M | 137.36M | 183.44M | 91.17M | 49.90M |
Total stockholder equity | 93.83M | 22.52M | -18.00600M | 8.40M | -5.41800M |
Deferred long term liab | - | - | 0.37M | - | - |
Other current liab | 14.08M | 11.13M | 8.15M | 13.49M | 11.70M |
Common stock | 0.01M | 0.01M | 0.01M | 0.00900M | 0.00300M |
Capital stock | 0.01M | 0.01M | 0.01M | 0.00900M | 0.00300M |
Retained earnings | -394.93700M | -430.31600M | -404.62900M | -335.75300M | -280.40300M |
Other liab | - | 36.84M | 67.45M | 56.23M | 14.76M |
Good will | - | - | - | - | - |
Other assets | 1.34M | 0.16M | 12.70M | 1.38M | 0.28M |
Cash | 106.44M | 114.06M | 138.69M | 89.89M | 37.40M |
Cash and equivalents | 106.44M | 114.06M | 138.69M | 89.89M | 37.40M |
Total current liabilities | 25.08M | 72.25M | 81.55M | 34.94M | 35.14M |
Current deferred revenue | 0.59M | 53.88M | 72.05M | 1.67M | 0.96M |
Net debt | -68.51300M | -78.77600M | -103.33700M | -70.61600M | -16.01800M |
Short term debt | 10.08M | 7.01M | 0.91M | 19.28M | 21.39M |
Short long term debt | 8.48M | 5.96M | - | 18.91M | 21.39M |
Short long term debt total | 37.92M | 35.28M | 35.35M | 19.28M | 21.39M |
Other stockholder equity | 493.31M | 457.39M | 391.18M | 348.66M | 279.54M |
Property plant equipment | 2.79M | 2.14M | 1.40M | 1.52M | 2.13M |
Total current assets | 148.14M | 144.44M | 151.34M | 96.67M | 42.08M |
Long term investments | 2.00M | 2.00M | - | - | - |
Net tangible assets | 93.83M | 22.52M | -18.00600M | 8.40M | -5.41800M |
Short term investments | 28.16M | 14.00M | - | - | 0.00000M |
Net receivables | 9.76M | 9.91M | 7.22M | 5.00M | - |
Long term debt | 17.79M | 19.67M | 24.79M | - | 0.00000M |
Inventory | - | - | - | - | - |
Accounts payable | 0.32M | 0.22M | 0.44M | 0.50M | 1.10M |
Total permanent equity | - | - | - | - | - |
Noncontrolling interest in consolidated entity | - | - | - | - | - |
Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
Accumulated other comprehensive income | -4.55800M | -4.56600M | -4.56300M | -4.52300M | -4.55700M |
Additional paid in capital | - | - | - | - | - |
Common stock total equity | 0.01M | 0.01M | 0.01M | 0.00900M | 0.00300M |
Preferred stock total equity | - | - | - | - | - |
Retained earnings total equity | -394.93700M | -430.31600M | -404.62900M | - | - |
Treasury stock | - | - | - | - | - |
Accumulated amortization | - | - | - | - | - |
Non currrent assets other | 1.34M | 1.47M | 1.75M | 1.38M | 0.28M |
Deferred long term asset charges | - | - | - | - | - |
Non current assets total | 17.75M | 15.44M | 14.09M | 2.90M | 2.41M |
Capital lease obligations | 11.66M | 9.65M | 10.55M | 0.37M | - |
Long term debt total | 17.79M | 19.67M | 24.79M | 0.00000M | 0.00000M |
Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
Investments | -13.80100M | -16.05500M | -0.74100M | 0.23M | 25.27M |
Change to liabilities | 1.70M | 1.44M | -2.81800M | -0.26300M | -0.61700M |
Total cashflows from investing activities | -15.00200M | -17.14000M | -0.74100M | 0.23M | 25.27M |
Net borrowings | - | - | 1.04M | -2.80000M | -2.80000M |
Total cash from financing activities | 39.22M | 52.90M | 14.43M | 105.04M | 0.70M |
Change to operating activities | - | -0.39000M | -7.17900M | 0.78M | -0.16400M |
Net income | 35.38M | -25.68700M | -68.87600M | -55.35000M | -65.33600M |
Change in cash | -7.39800M | -24.62800M | 48.51M | 53.87M | -33.34500M |
Begin period cash flow | 115.44M | 140.06M | 91.55M | 37.68M | 71.03M |
End period cash flow | 108.04M | 115.44M | 140.06M | 91.55M | 37.68M |
Total cash from operating activities | -31.63100M | -60.38200M | 34.88M | -51.43500M | -59.16100M |
Issuance of capital stock | 38.98M | 51.96M | 12.38M | 107.66M | 0.00000M |
Depreciation | 1.29M | 1.25M | 0.73M | 2.03M | 0.97M |
Other cashflows from investing activities | -13.80100M | -16.05500M | 0.07M | 0.28M | 26.16M |
Dividends paid | - | - | -0.18400M | -0.02800M | - |
Change to inventory | - | 0.21M | -7.17900M | 0.78M | - |
Change to account receivables | 3.32M | -2.69000M | -2.22400M | -5.00000M | -5.00000M |
Sale purchase of stock | 0.19M | 0.16M | 0.18M | 0.03M | 0.20M |
Other cashflows from financing activities | 0.05M | 0.78M | 21.37M | 0.18M | 0.50M |
Change to netincome | -8.88200M | 11.07M | 16.89M | 6.37M | 5.98M |
Capital expenditures | 1.20M | 1.08M | 0.81M | 0.05M | 0.88M |
Change receivables | 3.32M | -2.69000M | -2.22400M | - | - |
Cash flows other operating | -64.06100M | -45.82800M | 91.17M | - | - |
Exchange rate changes | - | -0.00300M | -0.05800M | - | - |
Cash and cash equivalents changes | -7.41800M | -24.62800M | 48.51M | - | - |
Change in working capital | -60.37700M | -48.19400M | 85.00M | -4.48100M | -0.78100M |
Stock based compensation | 11.19M | 7.72M | 5.42M | 5.16M | 5.71M |
Other non cash items | -19.11400M | 2.13M | 1.75M | 0.40M | 0.45M |
Free cash flow | -32.83200M | -61.46700M | 34.07M | -51.48200M | -60.04500M |
Sector: Healthcare Industry: Biotechnology
Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
---|---|---|---|---|---|---|---|---|
SELB Selecta Biosciences Inc |
- -% | - | - | 25.45 | 1.54 | 2.36 | 0.74 | 2.01 |
NVO Novo Nordisk A/S |
-0.53 0.41% | 129.83 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
NONOF Novo Nordisk A/S |
-1.53 1.17% | 129.50 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
VRTX Vertex Pharmaceuticals Inc |
3.60 0.87% | 415.71 | 30.40 | 24.75 | 10.68 | 6.25 | 9.52 | 20.36 |
CSLLY CSL Ltd |
-1.31 1.42% | 90.68 | 42.45 | 26.95 | 7.05 | 5.80 | 7.85 | 26.51 |
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in Phase I clinical trial to enhance the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura. In addition, the company is developing gene therapies comprising for the treatment of pompe disease, duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorder, and other autoimmune diseases. Further, it develops tolerogenic therapies to treat autoimmune diseases. The company has license and collaboration agreements with Ginkgo Bioworks Holdings, Inc.; Genovis AB (publ.); Cyrus Biotechnology, Inc.; IGAN Biosciences, Inc.; Astellas Therapeutics, Inc.; Takeda Pharmaceuticals USA, Inc.; Swedish Orphan Biovitrum AB (publ.); Sarepta Therapeutics, Inc.; Asklepios Biopharmaceutical, Inc.; Massachusetts Institute of Technology; and Shenyang Sunshine Pharmaceutical Co., Ltd. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.
65 Grove Street, Watertown, MA, United States, 02472
Name | Title | Year Born |
---|---|---|
Dr. Carsten Brunn Ph.D. | CEO, Pres & Director | 1971 |
Ms. Ann K. Donohue CPA | VP of Fin. & Controller | 1982 |
Dr. Lloyd Johnston Ph.D. | Chief Operating Officer | 1968 |
Dr. Takashi Kei Kishimoto Ph.D. | Chief Scientific Officer | 1960 |
Dr. Peter G. Traber M.D. | Chief Medical Officer | 1955 |
Dr. Ulrich H. von Andrian-Werburg M.D., Ph.D. | Co-Founder and Co-Chair of the Scientific Advisory Board | NA |
Mr. Blaine T. Davis | Chief Financial Officer | 1974 |
Mr. Matthew Bartholomae J.D. | Gen. Counsel & Sec. | NA |
Ms. Kristen Baldwin | Chief People Officer | NA |
Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).